Core Viewpoint - Sanxin Medical has received EU MDR certification for several medical products, indicating compliance with EU regulations and enhancing market access in EU countries and other regions recognizing this certification [1] Group 1: Certification Details - The products certified include single-use blood dialysis tubing, single-use blood collection devices, single-use sterile injection needles, single-use retractable self-destructing sterile syringes with needles, single-use precision filter infusion sets, single-use infusion sets, and single-use sterile dialysis care packages [1] - The certification type is EU Certificate, issued by TÜV Rheinland LGA Products GmbH, a German certification body [1] - The approval date for the certification is January 20, 2026, covering Class Ib, Class IIa, and Class Is products [1] Group 2: Market Implications - The certification signifies that the company has established a quality management system that meets EU MDR regulatory requirements [1] - This approval is expected to positively impact the promotion and sales of the company's products in EU countries and other nations that recognize EU MDR certification [1]

Market Overview - The medical device sector experienced a decline of 2.17% on January 28, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Individual Stock Performance - Notable gainers included: - Hualan Biological (301093) with a closing price of 80.77, up 1.87% and a trading volume of 61,400 shares, totaling 492 million yuan [1] - Cap Bio (300639) closed at 8.81, up 1.26% with a trading volume of 1.79 million shares, totaling 1.654 billion yuan [1] - Significant decliners included: - Huakang Clean (301235) closed at 46.40, down 8.66% with a trading volume of 118,300 shares, totaling 564 million yuan [2] - Zhijiang Biological (688317) closed at 24.13, down 8.49% with a trading volume of 198,200 shares, totaling 484 million yuan [2] Capital Flow Analysis - The medical device sector saw a net outflow of 2.057 billion yuan from institutional investors, while retail investors had a net inflow of 1.528 billion yuan [2] - The table of capital flow indicates that: - Innotec (688253) had a net inflow of 18.7598 million yuan from institutional investors [3] - Hualan Biological (301093) experienced a net inflow of 16.8935 million yuan from institutional investors [3]

九强生物公告，预计2025年度净利润为1.8亿元至2.18亿元，同比下降59.07%-66.21%。预计扣除非经常 性损益后的净利润为1.71亿元至2.11亿元，同比下降59.48%-67.16%。业绩变动主要由于资产减值计提和 主营业务受到医疗行业政策影响。 ...

Core Viewpoint - The company expects a net profit of 800 million to 1.2 billion yuan for the fiscal year 2025, representing a year-on-year growth of 223.97% to 385.95% [1] Group 1: Financial Performance - The core business of cardiovascular interventional revenue is steadily increasing [1] - The retail channel inventory clearance in the pharmaceutical sector's formulation business is nearly complete, achieving double-digit revenue growth [1] - The traditional business foundation remains solid, providing stable profits and cash flow for the company [1] Group 2: Strategic Developments - The strategic emerging sectors, including innovative drugs and dermatology, have contributed to performance growth [1] - The net cash flow generated from operating activities has increased by approximately 95% [1]

Core Viewpoint - Lepu Medical (300003.SZ) expects a net profit attributable to shareholders of 800 million to 1.2 billion yuan for 2025, representing a year-on-year growth of 223.97% to 385.95% [1] Group 1: Business Performance - The growth is primarily driven by steady increases in the cardiovascular interventional business and the completion of inventory clearance in the pharmaceutical retail channel, leading to double-digit growth in formulation revenue [1] - Contributions from innovative drugs and emerging sectors such as dermatology are also significant [1] Group 2: Financial Developments - The company received a $30 million upfront payment for the MWN105 project under a licensing agreement [1] Group 3: Cost Management - Personnel optimization and organizational restructuring have led to a decrease in sales and management expenses [1]

Core Viewpoint - The company expects a significant improvement in net profit for 2025, projecting a range of 12 million to 17.5 million yuan, compared to a loss of 118 million yuan in the same period last year [1] Revenue Performance - The company's operating revenue is anticipated to decline by 15% to 20% year-on-year [1] - The vacuum blood collection system products are primarily affected by a decrease in sales, leading to a downward trend in revenue [1] - Revenue from reagents, software products, and services is also expected to see a year-on-year decline [1] Cost Management - The company has implemented systematic cost optimization measures and refined management practices, effectively reducing manufacturing costs [1] - Despite a downward trend in product prices, the company has successfully achieved a slight increase in gross margin year-on-year [1] - The total expenses and expense ratio have decreased year-on-year due to reasonable control of expenditures and continuous optimization of the expense structure [1]

（来源：中国市场监管报） 转自：中国市场监管报 本报讯 近年来，面对医疗器械产业发展新形势、企业成长新诉求，江苏省太仓市市场监管局主动前移 服务端口，持续优化服务举措，用精准高效的服务举措破解医疗器械产业发展难题，为医疗器械产业发 展保驾护航。 "太感谢你们了，帮我们啃下'硬骨头'，让项目顺利落地。"日前，苏州新波生物技术有限公司负责人曹 佳飞带着锦旗，专程来到太仓市市场监管局表达谢意。2025年，该企业启动体外诊断试剂进口转国产项 目，210个产品需要完成备案才能推进本土化生产。但时间紧、任务重，加上中美关税政策调整的影 响，企业项目推进陷入困境。得知诉求后，该局第一时间响应，迅速指派专人全程对接，精准指导企业 填报材料、规避风险，同时优化内部审核流程，联动苏州市市场监管局打通跨层级审批堵点。最终仅用 两个月便完成全部产品备案任务，为企业争取了宝贵的投产时间。项目落地后，企业预计每年新增产值 2000万元。 聚焦服务企业，联合省药监局审评中心、省药监局审评核查苏州分中心开展企业专项服务26家次，审评 审批工作进一步提质增效。建设省药监局审评中心远程咨询服务点，提供注册申报前期指导、技术难题 解答、审评进度查 ...

Core Viewpoint - The company announced a share buyback plan aimed at employee stock ownership and equity incentives, with a budget of 15 million to 30 million yuan, and a maximum price of 25.32 yuan per share, valid until December 29, 2026 [1] Group 1 - The board meeting to approve the share buyback plan is scheduled for December 29, 2025 [1] - The first share repurchase occurred on January 28, 2026, with 272,800 shares bought back, representing 0.19% of the total share capital [1] - The transaction price for the initial buyback ranged from 18.05 to 18.43 yuan per share, with a total expenditure of 4.9714 million yuan [1]

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 1月28日，奥林巴斯官方宣布一项重要人事任命： 自 2026 年 3 月 2 日 起 ， 陈 小 穗 （ Rosa Chen ） 女 士 将 加 入 公 司 ， 出 任 奥 林 巴 斯 中 国 区 总 裁 ， 直 接 向 奥 林 巴 斯 全 球 总 裁、首席执行官兼董事Robert White汇报。 陈小穗女士， 2021年9月加入丹纳赫。2023年底晋升为丹纳赫中国医学诊断平台总裁，成为丹纳赫中国领导团队核 心成员。 此前，丹纳赫集团于1月13日宣布宣布原美敦力副总裁、中国骨科与神外业务总经理于婧将加入丹纳赫，接替陈小穗 （Rosa）任中国诊断平台总裁一职。 相关阅读： 新总裁将上任，丹纳赫中国诊断平台官宣 ↓ ↓ 加入行业讨论群 ↓ ↓ | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号立 场 | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 | 来 源 ： 仪 器 信 息 网 | ...

格隆汇1月28日丨塞力医疗(603716.SH)在投资者互动平台表示，目前公司暂无尼帕病毒病原学检测试剂/ 仪器或治疗药物储备，也暂无相关产品代理。我们的布局重点在"高危急性感染的早期识别与预警"能 力：基于战略投资并引进的Inflammatix TriVerity急性感染与脓毒症检测，可在症状极早期通过mRNA转 录组信号实现感染类型判断（病毒/细菌/非感染）及重症/脓毒症风险分层。对尼帕这类疑似病例， TriVerity可作为急诊/发热门诊的早期预警与分诊升级工具，提示更高等级隔离与监护、支持更快启动确 诊检测与救治流程，最终确诊仍需病原学检测配合。 （原标题：塞力医疗(603716.SH)：暂无尼帕病毒病原学检测试剂/仪器或治疗药物储备） ...